Alu- and 7SL RNA Analogues Suppress MCF-7 Cell Viability through Modulating the Transcription of Endoplasmic Reticulum Stress Response Genes

D.N. Baryakin1*, D.V. Semenov1, A.V. Savelyeva1,2, O.A. Koval1, I.V. Rabinov1, E.V. Kuligina1, V.A. Richter1
1Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, Lavrentiev Ave., 8, Novosibirsk, Russia, 630090
2Novosibirsk State University, Pirogova Str., 2, Novosibirsk, Russia, 630090
*E-mail: baryakindn@nibochnsc.ru
Received 14.08.2013
Copyright © 2013 Park-media, Ltd. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT 11% of the human genome is composed of Alu-retrotransposons, whose transcription by RNA polymerase III (Pol III) leads to the accumulation of several hundreds to thousands of Alu-RNA copies in the cytoplasm. Expression of Alu-RNA Pol III is significantly increased at various levels of stress, and the increase in the Alu-RNA level is accompanied by a suppression of proliferation, a decrease in viability, and induction of apoptotic processes in human cells. However, the question about the biological functions of Pol III Alu-transcripts, as well as their mechanism of action, remains open. In this work, analogues of Alu-RNA and its evolutionary ancestor, 7SL RNA, were synthesized. Transfection of human breast adenocarcinoma MCF-7 cells with the Alu-RNA and 7SL RNA analogues is accompanied by a decrease in viability and by induction of proapoptotic changes in these cells. The analysis of the combined action of these analogues and actinomycin D or tamoxifen revealed that the decreased viability of MCF-7 cells transfected with Alu-RNA and 7SL RNA was due to the modulation of transcription. A whole transcriptome analysis of gene expression revealed that increased gene expression of the transcription regulator NUPR1 (p8), as well as the transcription factor DDIT3 (CHOP), occurs under the action of both the Alu- and 7SL RNA analogues on MCF-7 cells. It has been concluded that induction of proapoptotic changes in human cells under the influence of the Alu-RNA and 7SL RNA analogues is related to the transcriptional activation of the genes of cellular stress factors, including the endoplasmic reticulum stress response factors.

KEYWORDS Alu-repeats; Alu-RNA; 7SL RNA; MCF-7 human breast adenocarcinoma cells.

ABBREVIATIONS FITC – fluorescein-5-isothiocyanate; ER – endoplasmic reticulum; MTT – 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide; JC-1 – 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzilimidazolo-carboycyanine iodide; SRP – signal recognition particle.

INTRODUCTION 45% of the human genome is composed of mobile elements, of which Alu-repeats are the most numerous, ~1.1 × 10⁶ copies, which accounts for 10.6% of nuclear DNA [1, 2]. In a variety of Alu-repeats of primates, several subfamilies are identified and classified into three main groups: AluJ, AluS, and AluY [3]. The copy number of representatives of evolutionarily ancient AluJ-repeats, which emerged in the genome about 80 million years ago, and intermediate AluS subfamilies (about 40 million years ago), has not increased in the human genome. AluY subfamily repeats (> 20 million years ago) still remain transpositionally active [4].

It is known that the formation of new copies of Alu-and related SINE-repeats in the genome of mammals occurs by a retrotransposition mechanism, which comprises a step for the production of RNA copies of SINE-DNA. Evolutionarily significant variations in the genome occur due to the “successful” events of retrotransposition of repeats in germ cells [5, 6]. However, it is known that RNA copies of genomic Alu-repeats (Alu-RNA) are present both in germ and in somatic human cells [7]. Alu-RNAs are synthesized by RNA polymerase III (Pol III) [8] and are a set of RNA copies of the “ancient,” transpositionally inactive Alu-repeats of the subfamilies J and S, and transpositionally active AluY [7, 9, 10]. Alu-RNAs, as well as their evolutionary ancestor, 7SL RNA, are synthesized in the nucleus and are then transported into the cytoplasm. Some Alu-transcripts undergo 3′-endonuclease processing to yield the truncated forms, scAlu-RNAs, represented by the “left” Alu monomers (Fig. 1A). Along with the
 truncated Alu-transcripts, unprocessed forms are determined in cells. The latter are represented by Alu-RNA, which includes the “left” and “right” monomers, and the 3’-terminal poly-A-sequence (Fig. 1A) [10, 11]. The number of full-length Pol III Alu-transcripts is \(10^2–10^3\) molecules per cell. Regulation of Alu-RNA expression in human cells differs from that of other Pol III-transcripts. Thus, a translation inhibitor, cycloheximide, and heat shock increase the expression of Alu-RNA to a greater extent compared with the expression of other Pol III-transcripts, such as 7SL, 7SK, 5S and u6 RNAs [8]. The permanent presence of full-length Alu transcripts in the cytoplasm, as well as an increase in the expression of these RNAs under stress, on one hand, indicates that Alu-RNA is a closely controlled endogenous factor of mutagenesis and, on the other hand, makes it possible to suggest that Alu-RNAs are regulators of vital cellular processes [12].

Earlier K. Sakamoto et al. [13] demonstrated that transfection of HeLa cells with DNA constructs containing transcriptionally active Alu-repeats, as well as with constructs encoding 7SL RNA, causes suppression of DNA replication, inhibits translation, and provides an antiproliferative effect. It was found that transfection of human embryonic kidney HEK 293 cells with DNA encoding Alu-repeats leads to specific activation of the expression of the reporter genes, presumably due to direct inhibition of the dsRNA-activated protein kinase PKR by Alu-RNA [14]. It was shown later [15] that activation of reporter gene expression in the presence of Alu-RNA was induced by a decrease in the lag period of translation of newly synthesized mRNAs and was not associated with inhibition of PKR. However, a new molecular mechanism, by which Alu-RNA might affect the translation initiation of newly synthesized mRNAs, was not proposed.

J. Häsl er and K. Strub assumed that the participation of Pol III Alu-transcripts in cellular processes was related to their structural similarity with 7SL RNA (Fig. 1) [12, 16]. Like 7SL RNA, Alu-RNA interacts with the proteins of the signal recognition particle (SRP) [17, 18]. The ability of Alu-RNA to modulate translation is attributed to its interaction with SRP9/14 proteins: it has been shown that Alu-RNA activates translation, but Alu-RNA in complex with SRP9/14 inhibits the in vitro translation of total mRNA in HeLa cells in wheat germ extracts [16].

It has been demonstrated in vitro that Alu-RNA directly interacts with the catalytic subunit of human RNA polymerase II (Pol II) and inhibits the activity of the complex Pol II-TBP-TFIIB-TFIIF at a step of transcription initiation [19, 20]. These data suggest that Alu-RNA is a nonspecific regulator of mRNA transcription in human cells [19].

Recently, in a study on the molecular and cellular mechanisms of the geographic atrophy of the retina (one of the main reasons for a decrease in visual acuity and blindness in people older than 50 years) it was found that retinal pigment epithelial cell death is accompanied by a decrease in the DICER1 gene expression and by the accumulation of the Pol III AluSc-transcript in these cells [21]. It was shown that the key enzyme in post-transcriptional microRNA processing, Dicer1 RNase, hydrolyzes Alu-RNA in vitro. A decreased expression of DICER1 leads to the accumulation of AluSc-RNA, which in turn suppresses the viability and induces the apoptotic death of the epithelial cells of the retina [21]. A molecular mechanism for the cytotoxic action of Alu-RNA in pigmented epithelial cells has been suggested. It includes the generation of reactive oxygen species by mitochondria, activation of NLPR3-inflammasomes, as well as activation of the MyD88-signaling cascade [22]. Thus, it is the increase in the Alu-RNA expression level that is considered as the main cause of cell death in the geographic atrophy of the retina. However, the question as to why Alu-RNA causes reactive oxygen species formation remains open [21, 22].
In this work, the AluYa5-RNA and 7SL RNA analogues were synthesized and a comparative analysis of their effect on the viability and activation of proapoptotic processes in MCF-7 human breast adenocarcinoma cells was performed. The effect of the Alu-RNA and 7SL RNA analogues, along with cytostatics (inhibitors of replication, transcription, translation, and cellular transport), on MCF-7 cells was also analyzed. It has been established that the proapoptotic processes induced in MCF-7 cells by the Alu-RNA and 7SL RNA analogues are modulated by tamoxifen and actinomycin D. The results of the whole transcriptome analysis of gene expression variation in cells transfected with the Alu-RNA and 7SL RNA analogues allow us to put forward a new mechanism of the cytotoxic action of these RNAs based on the activation of the ER stress response genes NUPR1, DDIT3, FOXRED2, and ASNS.

EXPERIMENTAL

Reagents

The following reagents were used in this work: MTT – 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (Sigma, USA); Trizol, Lipofectamine 2000 (Invitrogen, USA); Taq-polymerase, T7-RNA-polymerase (Fermentas, USA); propidium iodide, JC-1 indicator, staurosporine (Sigma, USA); annexin V–FITC conjugate (BD Pharmingen, USA); cisplatin (LENS-Farm, Russia); cycloheximide, actinomycin D (AppliChem, Germany); interferon-α (Microgen, Russia); methotrexate, monensin (Sigma, USA); tamoxifen (Veropharm, Russia), the human recombinant tumor necrosis factor-α (State Research Center of Virology and Biotechnology VECTOR, Novosibirsk, Russia), reverse transcriptase MoMLV, ribonucleoside triphosphates, deoxyribonucleoside triphosphates, and T4-poly nucleotide kinase (Biosan, Novosibirsk, Russia). Deoxyribonucleotides were synthesized in the Laboratory of Medicinal Chemistry, Institute of Chemical Biology and Fundamental Medicine (SB RAS).

Synthesis of the Alu- and 7SL RNA analogues

To obtain DNA templates, which are PCR products encoding the Alu- and 7SL RNA analogues under the T7 phage RNA polymerase promoter, genomic DNA of MCF-7 cells was amplified with the following primer pairs (T7-RNA polymerase promoter is shown with lowercase letters): AluYa5, chr6:104,183,151–104,183,559: 5’-ATTTGATTCG- GTTATTTCCAAGA-3’, 5’-atggctaatagcactcact -tatagggGAGAGTTCAGCTACAGAATTGAA-3’; 7SL, chr14:50,329,268–50,329,585: 5’-AAAGACGGGTCCTCAGTAT-3’, 5’-atggctaatagcactcacttaggg -TTCCAGCGTCTCCGACC-3’.

DNA templates were purified by electrophoresis in a 10% polyacrylamide gel (PAGE) under native conditions. DNA was eluted from the gel in the presence of 100 mM NaAc and then re-precipitated with 70% ethanol.

The human AluYa5-RNA and 7SL RNA analogues were synthesized in a buffer containing 40 mM Tris- HCl (pH 8.0), 6 mM MgCl₂, 10 mM DTT, 10 mM NaCl, 2 mM spermidine, 2 mM NTP, and 30 units T7 phage RNA polymerase at 37 °C for 2 hrs. DNA templates were digested in the presence of 1 unit DNase I at 37 °C for 40 min, and then DNase I was inactivated by incubation at 65 °C for 15 min.

Purification of the AluYa5-RNA and 7SL RNA analogues was performed on a MiLiChrom A-02 chromatography system (EcoNova, Russia) with re-precipitation with 70% ethanol in the presence of 100 mM NaAc. The primary structure of the analogues was confirmed by RNA reverse transcription, cDNA amplification, and sequencing by the Sanger method on an automatic sequenator, ABI 3730XL Genetic Analyzer (SB RAS Genomics Core Facility).

Analysis of the viability of MCF-7 cells transfected with the Alu- and 7SL RNA analogues

Human breast adenocarcinoma cells were cultured in a IMDM medium supplemented with 10 mM L-glutamine, 100 u/ml penicillin, 0.1 mg/ml streptomycin, 0.25 µg/ml amphotericin, and a 10% fetal bovine serum at 37 °C in a 5% CO₂ atmosphere. The cell number was counted in the Goryaev chamber.

MCF-7 cells were cultured in a 96-well plate until a 60-70% confluent monolayer was formed. The cells were transfected with 1 µg/ml RNA in a complex with Lipofectamine (Invitrogen, USA) according to the manufacturer’s protocol and were incubated for 24 or 72 hrs as indicated in the legends to Tables. The medium was added with MTT to a final concentration of 0.7 mg/ml and was incubated at 37 °C for 45 min. The medium was removed, MTT formazan was dissolved in isopropyl alcohol, and the solution’s optical density was determined by absorbance at λ=570 nm with the control at λ=620 nm using an Apollo LB 912 8 multichannel spectrophotometer (Berthold Technologies).

Analysis of proapoptotic changes in MCF-7 cells by flow cytometry

MCF-7 cells transfected with the Alu- and 7SL RNA analogues and the control cells incubated in the medium with Lipofectamine without RNA were washed three times with PBS and were incubated in the presence of 0.1 mg/ml trypsin at 37 °C for 5 min. To analyze cell membrane changes, a cell suspension was incubated in the presence of 4.5 µg/ml propidium iodide and annexin V–FITC conjugate according to the manufac-
turer’s protocol (BD Pharmingen, USA). A cell suspension was incubated with 2.5 µg/ml JC-1 to analyze the changes in the mitochondrial transmembrane potential (δΨ). Preparations were analyzed by flow cytometry on a Beckman Coulter FC 500 device according to the method described in [23]. MCF-7 cell preparations incubated with a 5 µg/ml tumor necrosis factor α or with 1 µM staurosporine for 24 hrs were used as a positive control of the proapoptotic changes.

Analysis of variations in the transcriptome of MCF-7 cells using Illumina chips

MCF-7 cells were transfected with 1 µg/ml Alu-RNA or with 1 µg/ml 7SL RNA and incubated at 37 °C in a 5% CO₂ atmosphere for 24 hrs. Cells incubated with Lipofectamine without RNA under the same conditions were used as a control. Hybridization of the total RNA of MCF-7 cells without RNA under the same conditions were used as a control. Hybridization of the total RNA of MCF-7 cells on HT-12 Illumina chips was performed on the basis of GenoaAnalytica, CJSC (Moscow). The differential analysis of the variations in gene expression was performed using the Illumina custom algorithm with data normalization by the rank invariant method. The parameter Detection_Pval < 0.05 was used to interpret the results of the differential analysis of gene expression variations. Upon interpretation of the data on an increase in the gene expression under the influence of Alu-RNA, transcripts for which the structure of hybridization probes (Illumina PROBE_SEQUENCE) contained direct sequences of Alu-repeats were excluded from consideration.

Sampling verification of the whole transcriptome analysis results was performed with the real-time RT-PCR method using the following primer pairs:

- P5FPH – 5’-ATGATGAGGAGATGGTCCAC-3’,
- 5’-CAGTTGATAATACCTTGGCC-3’;
- DDIT3 – 5’-GACCTGCAAGAGTCTCGT3’,
- 5’-AAGCCAGGGTCAAGAGTG-3’;
- MTHFD – 5’-TGTAGGACGAATGTGTTTGG-3’,
- 5’-AACATTGGCAATGGGCCATTCC-3’;
- TDP1 – 5’-CTCATCACTGATGATGCC-3’,
- 5’-TGACTTCCCCTGAAGCCTCC-3’;
- ZNF682 – 5’-AAGCCAGAGTATTAGGCC-3’,
- 5’-AAGGTCTTCAGTGTAATGAG-3’;
- CEBPG – 5’-CGCTCAGAGTGGAGCCGCC-3’,
- 5’-CAGGGTGATCAATGGTTTCC-3’.

GAPDH and HPRT mRNAs were used as normalization control [24].

RESULTS AND DISCUSSION

Influence of the Alu- and 7SL RNA analogues on the viability of human breast adenocarcinoma MCF-7 cells

The action of Alu-RNA and its evolutionary ancestor, 7SL RNA, on human cells was analyzed using an analogue of Alu-RNA, a transcript of human genomic repeat AluYa5, as well as using an analogue of 7SL RNA.

It was found that transfection of MCF-7 human breast adenocarcinoma cells with the Alu- and 7SL RNA analogues caused substantial morphological changes: condensation of the cytoplasm and nucleus, degradation of membrane contacts, and cell detachment from the plastic scaffold. The Alu- and 7SL RNA analogues induced morphological changes in approximately 20–30% of the cells by the 72nd h of incubation. Moreover, incubation in the medium with total MCF-7 RNA or with a L1-RNA moiety analogue or with Lipofectamine without RNA caused condensation and detachment from the scaffold of less than 5% of the MCF-7 cells.

The cells were incubated with the Alu- and 7SL RNA analogues, and their viability was analyzed using the MTT test to determine whether the morphological changes observed under the action of these analogues were caused by antiproliferative and proapoptotic processes.

The data presented in Table 1 demonstrate that the Alu-RNA and 7SL RNA analogues cause a statistically significant reduction in MCF-7 cell viability upon transfection with Lipofectamine (p < 0.05). The observed morphological changes in conjunction with the reduction in viability under the action of the Alu- and 7SL RNA analogues indicate that transfection with these RNAs leads to proapoptotic changes in cells.

We analyzed the changes in the mitochondrial transmembrane potential (δΨ) using the JC-1 indicator to evaluate, by an independent method, induction of the proapoptotic processes in MCF-7 cells under the influence of Alu- and 7SL RNAs. The indicator JC-1 forms aggregates in the mitochondria of viable cells, with the fluorescence spectrum shifted to the longer wavelengths (λ_max = 590 nm). Dissipation of the mitochondrial transmembrane potential δΨ is accompanied by a shift in the fluorescence spectrum maximum of the indicator to the green region (λ_max = 527 nm). The analysis of cell preparations by flow cytometry in the presence of the JC-1 indicator made it possible to estimate the relative contribution of a cell population to proapoptotic changes in the mitochondrial membrane [23, 25].

It was found that the reduction in MCF-7 cell viability under the action of the 7SL RNA analogue is accompanied by a reduction in the transmembrane potential δΨ in approximately 17% of the cells (Table 1). However, the action of 7SL RNA was not different from that of the Alu-RNA analogue (p > 0.05). Therefore, the data on the changes in the mitochondrial potential δΨ are consistent with the results of the viability analysis obtained using the MTT test, and with the evaluation of the depth of the morphological changes in the cells.
Transfection of cells with the Alu- and 7SL RNA analogues leads to the formation of cell-like structures exposing phosphatidylserine on the outer surface, as well as structures whose membrane is permeable to propidium iodide (apoptotic and secondary necrotic bodies). The overall contribution of the apoptotic and secondary necrotic bodies to the total population of cells transfected with the Alu-RNA analogue or 7SL RNA analogue was about 31% (Table 1).

It is known that the emergence of phosphatidylserine on the outer surface of the cytoplasmic membrane, detected by staining with annexin V, is one of the earliest biochemical signs of apoptosis [26]. Meanwhile, a decrease in the activity of mitochondrial and cytoplasmic oxidoreductases and a change in the NADH/NADPH level, detectable using the MTT test [27], are characteristic of the late stages of apoptosis. Therefore, the differences in the cytotoxic action of Alu- and 7SL RNAs, estimated from the reduction of the MTT-index (~ 15–19%) and from the induction of apoptotic processes by phosphatidylserine exposure and by plasma membrane permeability (~ 31%), can be attributed to the greater sensitivity of the approach using the annexin V/PI system.

Over all, these results suggest that analogues of both Alu-RNA and 7SL RNA reduce viability and induce proapoptotic changes in a MCF-7 cell subpopulation and that the effect of the Alu-RNA analogues is not significantly different from that of 7SL RNA at the level of the changes in the activity of cytoplasmic and mitochondrial dehydrogenases (MTT test), dissipation of the mitochondrial transmembrane potential \( \delta \Psi \), and by assessment of the depth of the morphological changes.

**Effect of Alu-RNA and RNA 7SL along with cytostatics on MCF-7 cell viability**

Key processes, the inhibition or activation of which occurs upon transfection of cells with the Alu-RNA and 7SL RNA analogues, were characterized by a change in the MCF-7 viability upon the combined action of the analogues and a series of cytostatic agents (Table 2). The combined action of RNAs and cellular process inhibitors was analyzed using such a cytostatic concentration in a culture medium at which MCF-7 cell viability was reduced by 40% \( (IC_{40}) \) by the 72nd h of incubation.

It is seen from the data in Table 2 that transfection of cells with the Alu- and 7SL RNA analogues enhances the cytotoxic action: for cisplatin by ~ 25 and 20%; for cycloheximide by ~ 18 and 15%; for interferon \( \alpha \) by ~ 18 and 27%, respectively \( (p < 0.05) \). Therefore, transfection with the Alu- and 7SL RNA analogues caused an unidirectional and comparable magnitude effect on MCF-7 cells for this set of effectors.

The formation of unreparable DNA crosslinks and suppression of replication and mitosis underlay the cytotoxic effect of cisplatin [28]. The additivity of cisplatin and Alu-RNA or 7SL RNA (Table 2) clearly indicates that the cytotoxic effects of this cytostatic agent and Alu-RNA or RNA 7SL are independent processes and the effects of these RNAs are related directly neither

```
Table 1. The effect of Alu-RNA and 7SL RNA analogues on the viability, asymmetry, cell membrane permeability, and mitochondrial transmembrane potential of MCF-7 cells

| RNA* | Decrease in viability (MTT-index ± SD, %)** | Proapoptotic changes in membrane*** | Mitochondrial transmembrane potential \( \delta \Psi \), % of cells |
|------|------------------------------------------|-----------------------------------|-------------------------------------------------|
|      |                                         | Ann V-/PI- Viable cells, %         | Ann V+/PI- Apoptotic bodies, %                  | Ann V+/PI+ Secondary necrotic cells, % |
|      |                                         |                                   |                                                 |                                  |
| 7SL RNA | 19.0 ± 4.8               | 69.2                           | 19.3                             | 11.5                           | 83.4                           | 16.6                           |
| Alu-RNA | 15.3 ± 6.5               | 68.7                           | 13.8                             | 17.5                           | 85.6                           | 14.4                           |
| RNA MCF-7 | −2.8 ± 8.2             | 85.2                           | 7.4                              | 7.3                            | 97.9                           | 2.1                            |
| Lipofectamine | 0 ± 2.5             | 89.9                           | 6.8                              | 3.3                            | 99.7                           | 0.3                            |
```

* Cells were transfected with 1µg/ml RNA in a complex with Lipofectamine.
** Viability of cells incubated in the medium with Lipofectamine without RNA was taken as 100%.
*** Changes in the cell membrane were analyzed by flow cytofluorometry using annexin V (AnnV) conjugated to FITC and propidium iodide (PI).
**** Dissipation of the mitochondrial transmembrane potential was evaluated using flow cytofluorometry of cells stained with the mitochondrial dye JC-1 [23].
to DNA replication nor to the activation of repair processes in MCF-7 cells.

The action of interferon α is based on the receptor-mediated transcriptional activation of interferon-induced genes, including the protein kinase PKR gene. PKR, in turn, is activated upon interaction with double-stranded RNA or with RNA comprising elongated hairpins, and it inhibits protein synthesis in the cell by phosphorylation of the translation initiation factor eIF2 [29]. Therefore, the additive action of the Alu- or 7SL RNA analogues and interferon α can be attributed to the fact that these RNAs, having a developed secondary structure (Fig. 1), induce the PKR-dependent suppression of translation in cells treated with interferon α: on the other hand, PKR activation by double-stranded RNA serves as a signal for the induction of innate immune cell response cascades and, as a consequence, as an interferonogenic stimulus [29]. Therefore, the PKR-dependent mechanism of the Alu- and 7SL RNA action provides manifold enhancement of the action of interferon α. At the same time, both Alu- and 7SL RNA cause the additive reduction of the MTT-index in interferon-stimulated cells, which is comparable to the reduction of viability upon combination of Alu- or 7SL RNA with cycloheximide or to the action of the RNAs without interferon α (Table 1, 2). Moreover, a number of studies have shown that the action of Alu-RNA on different processes in mammalian cells is directly connected neither to the developed secondary structure of these RNAs nor to the PKR activation [15, 21, 22]. Therefore, the PKR-dependent mechanism of action of structured RNAs and the interferonogenic activity of such RNAs only partially explain the induction of pro-apoptotic Alu- and 7SL RNA processes in MCF-7 cells.

7SL RNA, along with methotrexate and monensin, caused a significant decrease in the MTT-index (p < 0.05), but the variation of cell viability upon transfection with Alu-RNA, along with these cytostatic agents, was not statistically significant (Table 2). However, the decrease in the MTT-index of 7SL RNA in the presence of methotrexate or monensin was different from that induced by Alu-RNA along with these cytostatics (p < 0.05). These data demonstrate that the dihydrofolate reductase inhibitor methotrexate and ionophore monensin partially inhibit the cytotoxic effect of Alu-RNA, but not that of 7SL RNA.

An additional statistically significant reduction of viability (p > 0.05) in preparations of cells incubated in the medium with tamoxifen was not observed upon transfection with Alu-RNA or 7SL RNA (Table 2). Therefore, a conclusion can be drawn that tamoxifen partially suppresses the cytotoxic effect of both Alu-RNA and 7SL RNA on MCF-7 cells.

It is known that tamoxifen inhibits estrogen receptors, and that its effect on MCF-7 cells is due to a change in the transcription of estrogen-dependent genes. Tamoxifen is also an effective modulator of interferon action. The combined effect of interferon and tamoxifen synergistically reduces MCF-7 cell viability and induces their massive death both in culture and in a xenograft model [30, 31]. Thus, the partial inhibition of the cytotoxic effect of the Alu- and 7SL RNA analogues on MCF-7 cells by tamoxifen confirms the assumption that the influence of these RNAs on cell viability is not related to the potential interferonogenic properties of these structured RNAs.

### Table 2. Effect of Alu-RNA and 7SL RNA analogues on MCF-7 cell viability in the presence of cytostatic agents

| Effector (IC<sub>40</sub>) | Alu(+)-RNA | 7SL(+)-RNA |
|---------------------------|------------|------------|
|                           | MTT-index ± SD, % | p   | MTT-index ± SD, % | p |
| Cisplatin (9.5 µM)        | 25.7 ± 7.7  | 0.004      | 20.0 ± 3.5  | 0.001 |
| Cycloheximide (0.56 µM)   | 17.9 ± 6.7  | 0.010      | 14.9 ± 7.5  | 0.026 |
| Interferon α (400 U/ml)   | 17.8 ± 7.6  | 0.022      | 26.5 ± 7.9  | 0.009 |
| Methotrexate (33.3 µM)    | 11.5 ± 10.2 | 0.171      | 26.5 ± 8.4  | 0.011 |
| Monensin (2.5 pM)         | 3.8 ± 6.3   | 0.352      | 10.8 ± 5.1  | 0.021 |
| Tamoxifen (450 µM)        | -1.2 ± 12.7 | 0.897      | -12.1 ± 12.6| 0.244 |
| Actinomycin D (5.6 nM)    | 21.5 ± 21.2 | 0.232      | -57.7 ± 22.6| 0.031 |

* The empirically obtained effector concentrations are indicated at which cell viability decreased by 40% after incubation (with Lipofectamine) for 72 hrs.

** Additional decrease in the MTT-index in cells by the 72nd h after transfection with RNA. Viability of cells incubated in the medium with Lipofectamine, with an effector at the indicated concentration, and without RNA was taken as 0%.

*** p value for the Student’s t-test.
Actinomycin D, a DNA intercalator and an inhibitor of transcription and replication, completely inhibited the cytotoxic effect of the 7SL RNA analogue, while Alu-RNA, along with this cytostatic, caused no additional significant reduction of viability (Table 2). Taking into account that inhibition of replication with cisplatin did not reduce the effect of Alu- and 7SL RNA, it is possible to conclude that partial (in the case of Alu-RNA) and total (in the case of 7SL RNA) cessation of their cytotoxic action by actinomycin D is caused by the influence of these RNAs on transcription in human cells. The data on the compensation of the Alu- and 7SL RNA cytotoxic effect by the transcription modulator tamoxifen (Table 2) support the conclusion that the modulation of nuclear DNA transcription is the key element of the action mechanism of both Alu-RNA and its closest homologue, 7SL RNA, on MCF-7 cell viability.

Analysis of the variation in gene expression in MCF-7 cells under the influence of Alu- and 7SL RNA analogues

Genes whose expression varies under the action of the Alu- and 7SL RNA analogues were determined by the whole transcriptome analysis of MCF-7 cell RNA using Illumina HT-12 microarrays. Cells incubated in the medium with Lipofectamine without RNA were used as a control.

It was found that transfection of MCF-7 cells with Alu-RNA results in an increase in the expression of 68 transcripts by 3 and more times and in a decrease in the expression of 87 transcripts. Transfection of cells with 7SL RNA increased the level of 45 genes by 3 and more times and lowered the level of 74 genes. Thirteen transcripts common to Alu- and 7SL RNA were revealed in groups of transcripts with increased expression. Twenty-five transcripts common to Alu- and 7SL RNA were detected in the groups with lowered expression. These data demonstrate that Alu-RNA and 7SL RNA cause variations in differing sets of transcripts, and they suggest that there are also differences in the specificity of the influence and, possibly, in the induction mechanisms of the pro-apoptotic processes in human cells. However, a detailed analysis of the variation in the expression of the pro- and anti-apoptotic factors allowed us to determine a number of key processes common to cells transfected with both Alu-RNA and 7SL RNA.

It is seen from the data presented in Tables 3 and 4 that products of interferon-inducible genes such as OAS, ISG, IFIT, or STAT1 are almost absent from the list of transcripts whose expression is increased to the greatest extent [32]. Moreover, the analysis of GO-annotations in a group of 68 transcripts induced with Alu-RNA and in a group of 45 transcripts induced with 7SL RNA revealed no statistically significant (p < 10^-4) increase in the contribution of groups of the interferon response genes and innate immune response genes (data not shown). These results, again, confirm the conclusion that induction of proapoptotic processes in human cells with the Alu-RNA and 7SL RNA analogues cannot be explained by the activation of PKR, the interaction with TLR-receptors, or by another mechanism associated with the interferonogenic action of these RNAs.

Among the genes whose expression is increased under the action of both Alu-RNA and 7SL RNA (Tables 3, 4), NUPR1 stands out. It is known that the expression of the transcriptional regulator gene NUPR1 (encodes protein p8) is enhanced in response to various stress factors and results in cell resistance to chemotherapeutic agents, while a decrease in NUPR1 expression is accompanied by a suppression of cancer cell growth in vitro and in vivo [33, 34]. However, an increase in the level of NUPR1 mRNA also accompanies apoptotic changes in cancer cells [35].

The DDIT3 gene product, a CHOP transcription factor, is a key mediator of cell death in response to endoplasmic reticulum stress. Increased expression of this gene or microinjections of the CHOP protein cause dissipation of the mitochondrial transmembrane potential (ΔΨβ), generation of reactive oxygen species, and apoptotic cell death (a detailed consideration is provided in the review [36]) Therefore, the observed increase in the expression of the DDIT3 gene in MCF-7 cells under the action of the Alu- and 7SL RNA analogues (Tables 3, 4) is an essential proapoptotic stimulus. The increase in the expression of DDIT3 (CHOP) and induction of apoptosis in response to endoplasmic reticulum stress can be directly induced by NUPR1 (p8) gene activation, as has been shown in the case of the cannabinoid-induced apoptosis of astrocytoma cells U87MG [35].

It should be mentioned that an increase in the level of DDIT3 mRNA, as well as PSPH and MTHFD2 mRNAs, in MCF-7 cells under the influence of Alu-RNA or 7SL RNA (Tables 3, 4) was confirmed by random inspection of the results of a whole transcriptome analysis performed with the independent RT-PCR method (data not shown).

Expression of the FOXRED2 gene is reduced under the action of both Alu- and 7SL RNA (Tables 3, 4). The FOXRED2 gene product flavoprotein ERFAD participates in the transport of proteins from the endoplasmic reticulum into the cytoplasm. A reduction in the expression of this gene is associated with activation of proteotoxic stress in the endoplasmic reticulum [37]. Another sign of activation of the endoplasmic reticulum stress response is an increase in asparagine synthetase ASNS gene expression, whose transcription is activated by the CCAAT/enhancer binding protein CHOP [38].
### Table 3. MCF-7 cell transcripts whose level varies under the action of the Alu-RNA analogue

| Transcript | Identifier   | Relative change in expression | Annotation                                           |
|------------|--------------|------------------------------|------------------------------------------------------|
| **Increase in expression**                                                                |
| NUPR1      | NM_001042483 | 5.3                          | Nuclear protein, transcriptional regulator            |
| PER3       | NM_016831    | 5.1                          | Period homolog 3 (Drosophila)                        |
| TXNIP      | NM_006472    | 4.7                          | Thioredoxin interacting protein                      |
| ASNS       | NM_133436    | 4.5                          | Asparagine synthetase, transcript variant 1          |
| ZNF773     | NM_198542    | 4.3                          | Zinc finger protein 773                              |
| FAM119A    | NM_001127395 | 4.1                          | Family with sequence similarity 119, member          |
| ZNF750     | NM_024702    | 4.1                          | Zinc finger protein 750                              |
| PRRT2      | NM_145239    | 4.0                          | Proline-rich transmembrane protein 2                 |
| KCNE4      | NM_080671    | 3.9                          | Potassium voltage-gated channel                      |
| C6orf48    | NM_001040437 | 3.9                          | Chromosome 6 open reading frame 48                   |
| AUH        | NM_001698    | 3.8                          | AU RNA binding protein                               |
| DDIT3      | NM_004083    | 3.8                          | DNA-damage-inducible transcript 3                    |
| KRT81      | NM_002281    | 3.7                          | Keratin 81                                           |
| RNASE4     | NM_194430    | 3.6                          | Ribonuclease, RNase A family 4                       |
| FBXO15     | NM_152676    | 3.6                          | F-box protein 15                                     |
| FLJ45244   | NM_207443    | 3.6                          | DICER1 antisense RNA 1 non-coding RNA                |
| MTHFD2     | NM_001040409 | 3.5                          | Methyltetrahydrofolate dehydrogenase                |
| **Decrease in expression**                                                                |
| FOXRED2    | NM_024955    | 0.15                         | FAD-dependent oxidoreductase domain containing 2     |
| PPRC1      | NM_015062    | 0.19                         | Peroxisome proliferator-activated receptor gamma, coactivator-related 1 |
| CHP        | NM_007236    | 0.21                         | Calcium binding protein P22                          |
| PHLDA2     | NM_003311    | 0.21                         | Pleckstrin homology-like domain, family A, member 2  |
| TMEM158    | NM_015444    | 0.21                         | Transmembrane protein 158                            |
| ATN1       | NM_001007206 | 0.22                         | Atrophin 1 (ATN1)                                    |
| DLK2       | NM_206539    | 0.23                         | Delta-like 2 homolog (Drosophila)                    |
| HPS1       | NM_182639    | 0.23                         | Hermansky-Pudlak syndrome 1                          |
| TMEM214    | NM_017727    | 0.23                         | Transmembrane protein 214                            |
| MED24      | NM_014815    | 0.24                         | Mediator complex subunit 24                          |
| PLEC1      | NM_000445    | 0.24                         | Plectin 1, intermediate filament binding protein 500 kDa |
| ZYX        | NM_003461    | 0.24                         | Zyxin                                                |
| ACD        | NM_022914    | 0.25                         | Adrenocortical dysplasia homolog (mouse)             |
| PCDH7      | NM_002589    | 0.25                         | Protocadherin 7 (PCDH7)                              |
| RDH10      | NM_172037    | 0.25                         | Retinol dehydrogenase 10 (all-trans)                 |
| GPX2       | NM_002083    | 0.26                         | Glutathione peroxidase 2 (gastrointestinal)          |

* Transcripts annotated in the RefSeq database (accessions NM, NR). The transcripts whose expression changed under the action of both Alu-RNA and 7SL RNA are shown in grey.
** Variation in the transcript amount in cells treated with Alu-RNA relative to the control cells treated with Lipofectamine.
*** The Illumina HT-12 probe sequence for the FLJ45244 gene coincides with the DICER-AS1 sequence (NR_015415).
Table 4. MCF-7 cell transcripts whose level varies under the action of the 7SL RNA analogue

| Transcript* | Identifier | Relative change in expression** | Annotation |
|-------------|------------|---------------------------------|------------|
| **Increase in expression** | | | |
| NUPR1 | NM_001042483 | 4.5 | Nuclear protein, transcriptional regulator |
| TXNIP | NM_006472 | 4.3 | Thioredoxin interacting protein |
| PRRT2 | NM_145239 | 4.3 | Proline-rich transmembrane protein 2 |
| PSPH | NM_004577 | 4.2 | Phosphoserine phosphatase |
| ASNS | NM_133436 | 3.8 | Asparagine synthetase, transcript variant 1 |
| KY | NM_178354 | 3.8 | Kyphoscoliosis peptidase |
| FABP6 | NM_001445 | 3.7 | Fatty acid binding protein 6, ileal |
| DDIT3 | NM_004083 | 3.6 | DNA-damage-inducible transcript 3 |
| CTSK | NM_000396 | 3.6 | Cathepsin K |
| KRT81 | NM_002281 | 3.6 | Keratin 81 |
| PFAAP5 | NM_014887 | 3.4 | Phosphonoformate immuno-associated protein 5 |
| NT5E | NM_002526 | 3.4 | 5'-Nucleotidase, ecto (CD73) |
| ARL3 | NM_004311 | 3.4 | ADP-ribosylation factor-like 3 |
| ULBP1 | NM_025218 | 3.4 | UL16 binding protein 1 |
| BACE2 | NM_138992 | 3.4 | Beta-site APP-cleaving enzyme 2 |
| RNASE4 | NM_194431 | 3.3 | Ribonuclease, RNase A family 4 |
| **Decrease in expression** | | | |
| FOXRED2 | NM_024955 | 0.16 | FAD-dependent oxidoreductase domain containing 2 |
| GPX2 | NM_002083 | 0.16 | Glutathione peroxidase 2 (gastrointestinal) |
| TUBB2A | NM_001069 | 0.17 | Tubulin, beta 2A |
| PLEC1 | NM_000445 | 0.19 | Plectin 1, intermediate filament binding protein |
| ZC3HAV1 | NM_024625 | 0.20 | Zinc finger CCCH-type, antiviral 1 |
| SLC35C1 | NM_018389 | 0.21 | Solute carrier family 35, member C1 |
| NCOR2 | NM_001077261 | 0.21 | Nuclear receptor co-repressor 2 |
| PIGW | NM_178357 | 0.22 | Phosphatidylinositol glycan anchor biosynthesis, class W |
| MUC1 | NM_001044391 | 0.22 | Mucin 1, cell surface associated |
| OPA3 | NM_025136 | 0.23 | Optic atrophy 3 (autosomal recessive, with chorea and spastic paraplegia) |
| PDPK1 | NM_002613 | 0.23 | 3-Phosphoinositide dependent protein kinase-1 |
| SLC29A3 | NM_013844 | 0.23 | Solute carrier family 29 (nucleoside transporters), member 3 |
| HCFC1 | NM_005334 | 0.24 | Host cell factor C1 (VP16-accessory protein) |
| FAHD1 | NM_001018104 | 0.24 | Fumarylacetocacetate hydrolase domain containing 1 (FAHD1) |
| PARP12 | NM_022750 | 0.24 | poly (ADP-ribose) polymerase family, member 12 |
| LRRC14 | NM_014665 | 0.25 | Leucine rich repeat containing 14 |

*Transcripts annotated in the RefSeq database (accessions NM, NR). The transcripts whose expression changed under the action of both Alu-RNA and 7SL RNA are shown in grey.

**Variation in the transcript amount in cells treated with Alu-RNA relative to the control cells treated with Lipofectamine.
Therefore, the decrease in \textit{FOXRED2} expression, observed simultaneously with an increase in the level of \textit{NUPR1} (p8), \textit{DDIT3} (CHOP), and \textit{ASNS}, suggests that induction of the proapoptotic processes in MCF-7 cells under the influence of Alu- and 7SL RNAs is associated with modulation of the transcription of the key cellular factors of the endoplasmic reticulum stress response.

A new mechanism for the development of geographic atrophy of the retina has recently been proposed, which is based on a decrease in \textit{DICER1} expression in the epithelial cells and enhanced expression of Alu-RNA [21]. Subretinal transfection of cells with a construct encoding 7SL RNA, as well as with a 7SL RNA analogue, did not lead to degeneration of the retinal pigment epithelium in mice in contrast to transfection with Alu-RNA [21, 22]. It has been suggested that the cytotoxic effect of Alu-RNA on retinal pigment epithelial cells is associated with unidentified properties of Alu-RNA, and that the mechanism of action is associated with the generation of reactive oxygen species by mitochondria [22].

Our data demonstrate that both Alu- and 7SL RNAs cause comparable changes in the mitochondrial transmembrane potential of MCF-7 cells (Table 1). Consequently, both Alu-RNA and 7SL RNAs induce similar changes in the mitochondrial membrane at least in MCF-7 cells. The analysis of the action of Alu- and 7SL RNAs, along with actinomycin D and tamoxifen, on MCF-7 cell viability revealed that the cytotoxic effect of these RNAs was caused by transcription modulation. The data on the variation of gene expression (Tables 3, 4) demonstrate that transfection of cells with Alu-RNA or 7SL RNA analogues is accompanied not only by a nonspecific response to exogenous RNA, an increase in the levels of \textit{RNASe4} ribonuclease mRNA and \textit{NT5E} 5′-ectonucleotidase mRNA, but also by the emergence of proapoptotic stimuli: \textit{NUPR1}, \textit{DDIT3}, \textit{FOXRED2}. While \textit{NUPR1} gene expression is induced in response to a wide range of stress factors, \textit{DDIT3} and \textit{FOXRED2} are specifically related to the endoplasmic reticulum stress response. The \textit{DDIT3} gene product, the CHOP protein, is the key apoptosis inducer in the proteotoxic ER stress response. The obtained data suggest a mechanism of Alu- and 7SL RNA proapoptotic action which includes activation of the transcription of the \textit{NUPR1} (p8) and proapoptotic \textit{DDIT3} genes. The product of the latter, CHOP, induces apoptosis through the mitochondrial pathway in a MCF-7 cell subpopulation (Fig. 2).

Since 7SL RNA is a component of the signal recognition particle and Alu-RNA is capable of interacting with the proteins SRP9/14, it can be assumed that activation of the endoplasmic reticulum stress response with Alu- and 7SL RNA analogues is caused by a mal-function of this very component translational machinery of human cells.

**CONCLUSIONS**

It was found previously that an increase in the expression of Alu-RNA in human cells causes the suppression of DNA replication, inhibits translation, and exerts an antiproliferative effect. Our data indicate that nuclear RNA transcription is the key process that mediates the decrease in the viability of MCF-7 human adenocarcinoma cells under the action of both Alu-RNA and 7SL RNA analogues. However, no activation of the expression of interferon-inducible genes is observed. Meanwhile, transfection of MCF-7 cells with Alu-RNA or 7SL RNA is accompanied by changes in the expression of a number of genes, including \textit{NUPR1}, \textit{DDIT3}, \textit{FOXRED2}, and \textit{ASNS}. Variation in the transcription of these genes is known to be associated with the complex cell response to ER stress, which is capable of inducing the formation of reactive oxygen species and cell death.
through the mitochondrial apoptosis pathway. Activation of the ER stress response under the influence of Alu- and 7SL RNA analogues is presumably associated with SRP malfunction in cells.

On the whole, our results and published data indicate that Alu-RNA is not only a marker, but also a mediator of cell stress signals.

This work was supported by the Russian Foundation for Basic Research (grant № 13-04-01058), and by the interdisciplinary integration project of the Presidium of the Siberian Branch of RAS № 84 (2012–2014).

REFERENCES
1. International Human Genome Sequencing Consortium // Nature. 2001. V. 409. № 6822. P. 860–921.
2. Deininger P.L., Batzer M.A. // Genome Res. 2002. V. 12. № 10. P. 1455–1465.
3. Batzer M.A., Deininger P.L., Hellmann-Blumberg U., Jurka J., Labuda D., Rubin C.M., Schmid C.W., Zietkiewicz E., Zuckerkandl E. // J. Mol. Evol. 1996. V. 42. № 1. P. 3–6.
4. Jurka J., Kranjac M., Kapitonov V.V., Stenger J.E., Kohany O. // Theor. Popul. Biol. 2002. V. 61. № 4. P. 519–530.
5. Dewannieux M., Esnault C., Heidmann T. // Nat. Genet. 2003. V. 35. № 1. P. 41–48.
6. Batzer M.A., Deininger P.L. // Nat. Rev. Genet. 2002. V. 3. № 5. P. 370–379.
7. Liu W.M., Marra R.J., Rubin C.M., Schmid C.W. // Nucleic Acids Res. 1994. V. 22. № 6. P. 1087–1095.
8. Liu W.M., Chu W.M., Choudary P.V., Schmid C.W. // Nucleic Acids Res. 1995. V. 23. № 10. P. 1758–1765.
9. Shaikh T.H., Roy A.M., Kim J., Batzer M.A., Deininger P.L. // J. Mol. Biol. 1997. V. 271. № 2. P. 222–234.
10. Marra R.J., Driscoll C.T., Bilyeu T., Hsu K., Darlington G.J. // Mol. Cell Biol. 1993. V. 13. № 7. P. 4233–4241.
11. Sarrowa J., Chang D.Y., Marra R.J. // Mol. Cell Biol. 1997. V. 17. № 3. P. 1144–1151.
12. Häsler J., Strub K. // Nucleic Acids Res. 2006. V. 34. № 19. P. 5491–5497.
13. Sakamoto K., Fordis C.M., Corsico D.D., Howard T.H., Howard B.H. // J. Biol. Chem. 1991. V. 266. № 5. P. 3031–3038.
14. Chu W.M., Ballard R., Carpick B.W., Williams B.R., Schmid C.W. // Mol. Cell Biol. 1998. V. 18. № 1. P. 58–63.
15. Rubin C.M., Kimura R.H., Schmid C.W. // Nucleic Acids Res. 2002. V. 30. № 14. P. 3253–3261.
16. Hasler J., Strub K. // Nucleic Acids Res. 2006. V. 34. № 8. P. 2374–2385.
17. Bovia F., Wolff N., Ryser S., Strub K. // Nucleic Acids Res. 1997. V. 25. № 3. P. 318–326.
18. Chang D.Y., Hsu K., Marra R.J. // Nucleic Acids Res. 1996. V. 24. № 21. P. 4165–4170.
19. Mariner P.D., Walters R.D., Espinoza C.A., Drilling J.F., Wagner S.D., Kugel J.F., Goodrich J.A. // Mol. Cell. 2008. V. 29. № 4. P. 499–509.
20. Yakovchuk P., Goodrich J.A., Kugel J.F. // Proc. Natl. Acad. Sci. USA. 2009. V. 106. № 14. P. 5569–5574.
21. Kaneko H., Dridi S., Tarallo V., Gelfand B.D., Fowler B.J., Cho W.G., Kleinman M.E., Ponicsan S.L., Hauswirth W.W., Chiodo V.A., et al. // Nature. 2011. V. 471. № 7338. P. 325–330.
22. Tarallo V., Hirano Y., Gelfand B.D., Dridi S., Kerur N., Kim Y., Cho W.G., Kaneko H., Fowler B.J., Bogdanovich S., et al. // Cell. 2012. V. 149. № 4. P. 847–859.
23. Galluzzi L., Vitale I., Kepp O., Seror C., Hangen E., Perfettini J.L., Modjtabahi N., Kroemer G. // Methods Enzymol. 2008. V. 442. P. 355–374.
24. Stepanov G.A., Semenov D.V., Savelyeva A.V., Kuligina E.V., Koval O.A., Rabinov I.V., Richter V.A. // Biomed. Res. Int. 2013. P. 656158.
25. Kroemer G., Galluzzi L., Brenner C. // Physiol. Rev. 2007. V. 87. № 1. P. 99–163.
26. Demchenko A.P. // Exp. Oncol. 2012. V. 34. № 3. P. 263–268.
27. Berridge M.V., Herst P.M., Tan A.S. // Biotechnol. Annu. Rev. 2005. V. 11. P. 127–152.
28. Siddik Z.H. // Oncogene. 2003. V. 22. № 47. P. 7265–7279.
29. Balachandran S., Barber G.N. // Meth. Mol. Biol. 2007. V. 383. P. 277–301.
30. Lindner D.J., Kolla V., Kalvakolanu D.V., Borden E.C. // Mol. Cell Biochem. 1997. V. 167. № 1–2. P. 169–177.
31. Iacopino F., Robustelli della Cuna G., Sica G. // Int. J. Cancer. 1997. V. 71. № 6. P. 1103–1108.
32. Der S.D., Zhou A., Williams B.R., Silverman R.H. // Proc. Natl. Acad. Sci. USA. 1998. V. 95. № 26. P. 15623–15628.
33. Goruppi S., Iovanna J.L. // J. Biol. Chem. 2010. V. 285. № 3. P. 1577–1581.
34. Guo X., Wang W., Hu J., Feng K., Pan Y., Zhang L., Feng Y. // Anat. Rec. (Hoboken). 2012. V. 295. № 12. P. 2114–2121.
35. Carracedo A., Lorente M., Egia A., Blázquez C., García S., Giroux V., Malicet C., Vilhuendas R., Gironeilla M., González-Feria L., et al. // Cancer Cell. 2006. V. 9. № 4. P. 301–312.
36. Tabas I., Ron D. // Nat. Cell Biol. 2011. V. 13. № 3. P. 184–190.
37. Riemer J., Appenzeller-Herzog C., Johansson L., Bodenmiller B., Hartmann-Petersen R., Elggaard L. // Proc. Natl. Acad. Sci. USA. 2009. V. 106. № 35. P. 14831–14836.
38. Siu F., Chen C., Zhong C., Kilberg M.S. // J. Biol. Chem. 2001. V. 276. № 51. P. 48100–48107.